Envudeucitinib

Phase 3

AAlumis Inc

Envudeucitinib is one of 9 therapeutic programs targeting Plaque Psoriasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Plaque PsoriasisActive, not recruiting

SLEActive, not recruiting

Plaque PsoriasisPhase 3

Active, not recruiting

SLEPhase 2

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Plaque Psoriasis

#DrugCompanyPhaseTrials

Sotyktu

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

5 2

Envudeucitinib

AAlumis Inc

Phase 3

3 3

ESK-001

AAlumis Inc

Phase 2

3 4

ORKA-002

OOruka Therapeutics, Inc.

Phase 2

1 5

ORKA-001

OOruka Therapeutics, Inc.

Phase 2

3 6

ZP9830

Zealand Pharma

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

SLE

NCT05966480

Q4 2027

Phase 2Active, not recruiting

Plaque Psoriasis

NCT05739435

Clinical

Trials by Indication[1]

Plaque Psoriasis3 trials

A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis (ONWARD1)

Completed·AAlumis Inc·Phase 3·NCT06586112·912 enrolled

A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)

Completed·AAlumis Inc·Phase 3·NCT06588738·862 enrolled

A Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Patients With Plaque Psoriasis

Active, not recruiting·AAlumis Inc·Phase 2·NCT05739435·165 enrolled

SLE1 trial

A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patients With Systemic Lupus Erythematosus

Active, not recruiting·AAlumis Inc·Phase 2·NCT05966480·408 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Envudeucitinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Envudeucitinib. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Alumis Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AAlumis Inc

Envudeucitinib

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Trials by Indication[1]

Plaque Psoriasis3 trials

SLE1 trial

References

Drug Info

Quick Facts

Related News